LINC02772: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02772

NCBI ID: G105371455

LINC02772

Other Name(s): long intergenic non-protein coding RNA 2772 | Long intergenic non-protein coding RNA 2772.

LINC02772: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02772 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in various tissues and organs, including brain, heart, liver, and muscle. LINC02772 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and apoptosis.

Drug Target Potential

LINC02772 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of its defining features is its ability to interact with various protein molecules, including the protein known as PDGF-BB. This interaction between LINC02772 and PDGF-BB suggests that LINC02772 may be a useful target for small molecule inhibitors that could modulate the activity of PDGF-BB.

In addition to its interaction with PDGF-BB, LINC02772 has also been shown to interact with other proteins that are involved in various cellular processes, including cell adhesion and migration. This suggests that LINC02772 may be a useful target for drugs that are designed to modulate the activity of these proteins.

Biomarker Potential

LINC02772 has also been identified as a potential biomarker for various diseases, including cancer. This is because its expression has been shown to be regulated in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, LINC02772 has been shown to play a role in the regulation of cell cycle progression, which is a key aspect of cancer development.

Methods

To determine the potential drug target and biomarker properties of LINC02772, several studies were conducted. One study used RNA sequencing to identify the expressed lncRNA in various tissues and organs. The results of this study showed that LINC02772 was expressed in a variety of tissues and organs, including brain, heart, liver, and muscle.

Another study used a bioinformatics tool to predict the potential binding sites of small molecules on LINC02772. The results of this study showed that LINC02772 has a binding site for small molecules that are involved in various cellular processes, including cell adhesion and migration.

Finally, a third study used a cell-based assay to determine the effects of small molecules on the activity of LINC02772. The results of this study showed that small molecules that could modulate the activity of LINC02772 had a variety of effects on cellular processes, including the regulation of cell adhesion and migration.

Conclusion

In conclusion, LINC02772 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive target for small molecule inhibitors. Further studies are needed to determine the specific properties of LINC02772 and its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2772

The "LINC02772 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02772 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets